Identification of Her-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8

Human Immunology

Volumn 52, Issue 2, 1997, Pages 109-118

  Lustgarten, Joseph ^b   Theobald, Matthias ^b   Labadie, Colleen ^b   LaFace, Drake ^b   Peterson, Per ^b   Disis, Mary L ^b   Cheever, Martin A ^b   Sherman, Linda A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN;

ANIMAL CELL; ARTICLE; CANCER; CARCINOGENESIS; HUMAN; HUMAN CELL; IMMUNOGENICITY; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTO ONCOGENE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD8; EPITOPES; FEMALE; GENE EXPRESSION; HLA-A2 ANTIGEN; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGOPEPTIDES; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0030944190     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(96)00292-3     Document Type: Article

References (51)

1. Townsend A, Bodmer H: Antigen recognition by class I-restricted T lymphocytes. Ann Rev Immunol 2:601, 1989.
2. Melief CJM: Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 58:143, 1992.
3. Bruggen Pvd, Traversari C, Chomez P, Lurquin C, Plaen ED, Eynde BVd, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643, 1991.
4. Bakker AB, Schreurs MW, deBoer AJ, Kawakami Y, Rosenberg, SA, Adema GJ, Figdor CG: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179: 1005, 1994.
5. Brichard V, Pel AV, Wolfel T, Wolfel C, Plaen ED, Lethe B, Coulie P, Boon TT: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489, 1993.
6. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian S L, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:3515, 1994.
7. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ: HER 2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54:3387, 1994.
8. Disis ML, Smith JW, Murphy AE Chen W, Cheever MA: In vitro generation of human cytolytic T-cells specific for peptides deried from the Her-2/neu protooncogene protein. Cancer Res 1071, 1994.
9. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cellular Immunol 151:225, 1993.
10. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109, 1995.
11. Whiteside TL, Parmiani G: Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother 39:15, 1994.
12. Weidmann E, Trucco M, Whiteside TL: Relevance of the T cell receptor for immunotherapy of cancer. Cancer Immunol Immunother 39:1, 1994.
13. Hayakama K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach EC, Legha SS, Balch CM, Ross MI, Augustus LB, Itoh K: Study of tumor-infiltrating lymphocytes for adoptive therapy of renal-cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J Immunother 10:313, 1991.
14. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa A C: Alteration in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795, 1992.
15. Ochoa AC, Longo DL: Alteration of signal transduction in T cells from cancer patients. In: Imp Adv Oncol 43-54, 1995 (monograph).
16. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, Finke JH: T-cells infiltrating renal cell carcinoma display a poor proliferative response even thugh they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 53:1380, 1993.
17. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53:5613, 1993.
18. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J-L, Vivier E, Anderson P, Kiessling R: Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610, 1993.
19. Vitiello A, Marchesini D, Furze J, Sherman LA, Chestnut RW: Analysis of the HLA-restricted influenza-specific CTL response in transgenic mice carrying a chimeric human-mouse class I MHC molecule. J Exp Med 173:1007, 1991.
20. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA: Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 92:11993, 1995.
21. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, Sidney J, Guercio M-FD, Southwood S, Kubo RT, Chesnut, RW, Grey HM, Chisari FV: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153:5586, 1994.
22. Sherman LA, Hesse SV, Irwin MJ, Face DL, Peterson P: Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 258:815, 1992.
23. Man S, Ridge JP, Engelhard VH: Diversity and dominance among TCR recognizing HLA-A2.1+ influenza matrix peptide in human MHC class I transgenic mice. J Immunol 153:4458, 1994.
24. Wentworth PA, Vitiello A, Sidney J, Keogh E, Chesnut RW, Grey H, Sette A: Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 26:97, 1996.
25. Irwin MJ, Heath WR, Sherman LA: Species-restricted interactions between CD8 and the α3 domain of class I influence the magnitude of the zenogenic response. J Exp Med 170:1091, 1989.
26. Kalinke U, Arnold B, Hammerling GJ: Strong xenogeneic HLA response in transgenic mice after introducing an α3 domain into HLA B27. Nature 348:642, 1990.
27. Samberg NL, Scarlett EC, Stauss HJ: The α3 domain of major histocompatibility complex class I molecules play a critical role in cytotoxic T lymphoyocyte stimulation. Eur J Immunol 19:2349, 1989.
28. LaFace DM, Vestberg M, Yang Y, Srivastava R, DiSanto J, Flomenberg N, Brown S, Sherman LA, Peterson PA: Human CD8 coreceptor regulation of HLA recognition by murine T cells. J Exp Med 182:1315, 1995.
29. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A: Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929, 1993.
30. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230, 1986.
31. Sette A, Buus S, Colon S, Miles C, Grey HM: Structural analysis of peptides capable of binding to more than one 1a antigen. J Immunol 142:0035, 1989.
32. Morrison J, Elvin J, Latron F, Gotch F, Moots R, Strominger JL, McMichael A: Identification of the nonamer peptide from influenze A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur J Immunol 22:903, 1992.
33. Parham P, Bodmer WF: Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2. Nature 276: 397, 1978.
34. Storkus WJ, Zeh HJ, Maurer MJ, Salter RD, Lotze MT: Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 151:3719, 1993.
35. Fisk B, Ioannides CG, Aggarwal S, Wharton JT, O'Brian CA, Restifo N, Glisson BS: Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line. Lympho Cytokine Res 13:125, 1994.
36. Fady C, Gardner A, Gera JF, Lichtenstein A: Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events. Cancer Immunol Immunother 37:329, 1993.
37. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W: Human breast cancer: correlation of relapse and survival with amplification on the HER-2/neu oncogene. Science 235:177, 1987.
38. DePotter CR, Quatacker J, Maertens G, Daele SV, Pauwels C, Verhofstede C, Eechaute W, Roels H: The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 44:969, 1989.
39. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432, 1995.
40. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. Exp Med 183:87, 1996.
41. Porgador A, Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182:255, 1995.
42. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M, Oserof C, Grey HM, Melief CJM, Kast WM: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*-201-binding peptides. J Immunol 154:5934, 1995.
43. Udaka K, Tsomide TJ, Eisen HN: A naturally occurring peptide recognized by alloreactive CD8 + cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69:989, 1992.
44. Nistico P, Tecce R, Giacomin, P, Cavallari A, Dagnano I, Fisher PB, Natali PG: Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res 50:7422, 1990.
45. Greiner JW, Guadagni F, Hand PH, Pestka S, Noguchi P, Fisher PB, Scholm J: Augmentation of tumor antigen expression by recombinant human interferons: enhanced targeting of monoclonal antibodies to carcinomas. Cancer Treat Res 51:413, 1990.
46. Mortarini R, Belli F, Parmiani G, Anachini A: Cytokine-mediated modulation of HLA-class II, ICAM-1. LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-β, rTNF-α, rIFN-γ, rIL4 and their combinations. Int J Cancer 45:334, 1990.
47. Schmidt-Wolf G, Schmidt-Wolf IG: Cytokines and clinical gene therapy. Eur J Immunol 25:1137, 1995.
48. Bargmann C, Hung M, Weinberg R: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226, 1986.
49. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A: Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 45:457, 1990.
50. Press MF, Cordon-Cardo C, Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953, 1990.
51. Boon T, Cerottini JC, Eynde BVd, Gruggen PVd, Pel AV: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337, 1994.